MELPHALAN FLUFENAMIDE for Plasma cell myeloma refractory: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 7 adverse event reports in the FDA FAERS database where MELPHALAN FLUFENAMIDE was used for Plasma cell myeloma refractory.
Most Reported Side Effects for MELPHALAN FLUFENAMIDE
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Platelet count decreased | 11 | 12.4% | 1 | 1 |
| Drug ineffective | 10 | 11.2% | 1 | 6 |
| Nausea | 9 | 10.1% | 1 | 0 |
| Cytopenia | 8 | 9.0% | 2 | 3 |
| Sepsis | 8 | 9.0% | 4 | 6 |
| Thrombocytopenia | 8 | 9.0% | 1 | 1 |
| Neutropenia | 7 | 7.9% | 1 | 0 |
| White blood cell count decreased | 7 | 7.9% | 2 | 1 |
| Anaemia | 5 | 5.6% | 1 | 1 |
| Diarrhoea | 5 | 5.6% | 2 | 0 |
| Disease progression | 5 | 5.6% | 1 | 0 |
| Fatigue | 5 | 5.6% | 1 | 1 |
| Off label use | 5 | 5.6% | 1 | 1 |
Other Indications for MELPHALAN FLUFENAMIDE
Other Drugs Used for Plasma cell myeloma refractory
DEXAMETHASONE (2,276)
POMALIDOMIDE (1,562)
LENALIDOMIDE (1,220)
CARFILZOMIB (1,208)
BORTEZOMIB (848)
DARATUMUMAB (789)
ISATUXIMAB (778)
CYCLOPHOSPHAMIDE (518)
IXAZOMIB (356)
DOXORUBICIN (314)